SEATTLE, April 1, 2013 /PRNewswire/ -- Eric Holland, M.D., Ph.D., an internationally renowned neurosurgeon and brain cancer researcher, has been recruited from Memorial Sloan-Kettering Cancer Center to Fred Hutchinson Cancer Research Center and the University of Washington to establish world-class research programs on brain and other solid-tumor cancers in Seattle. He will arrive this summer.
At Fred Hutch, where Holland's research laboratory will be based, he will be senior vice president and director of the Human Biology Division, an interdisciplinary program that encourages collaboration among faculty with a broad range of expertise – from molecular and cellular biology to genetics and clinical research. This unique structure fosters laboratory-based, computational and clinical research that yields discoveries which can be rapidly translated into treatments for cancer patients.
He will replace Denise Galloway, Ph.D., interim director and member of the Human Biology Division, who assumed that role in May 2011 upon the retirement of former division Director Barbara Trask, Ph.D."As a practicing neurosurgeon with an outstanding track record in molecular biology and genetics, Eric is at the forefront of translating laboratory advances into advanced molecular therapeutics – expertise that will be instrumental in catalyzing our efforts to build strength in clinical molecular diagnostics and precision oncology," said Larry Corey, M.D., president and director of Fred Hutch. "I am confident that Eric will help us apply the strategies he has developed and used so successfully for brain tumors to many other types of solid-tumor cancers. His recruitment will catalyze numerous opportunities of this kind for our institutions," he said. With advances in genomics increasingly playing an important role in solid-tumor oncology, Holland's expertise will provide strong leadership in this area, strengthening Seattle's reputation in translational, solid-tumor research. At Fred Hutch, Holland will oversee the recruitment of new laboratory-based investigators who are at the forefront of solid-tumor translational research in areas such as breast, prostate, gastrointestinal and other cancers.